Pramlintide (Symlin) for diabetes

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1209, 2005, Pages 43-44

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHOLINERGIC RECEPTOR BLOCKING AGENT; INSULIN; MIGLITOL; PRAMLINTIDE; AMYLIN; AMYLOID;

ANOREXIA; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY; VOMITING; WEIGHT REDUCTION; ARTICLE; INJECTION; INSULIN INFUSION;

AMYLOID; DIABETES MELLITUS; HUMANS; INJECTIONS; INSULIN INFUSION SYSTEMS;

EID: 21544443445     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. C Weyer et al. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm 2005; 62:816.
2. F Whitehouse et al. A randomized study and open label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25:724.
3. R Ratner et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21:1204.
4. RG Thompson et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 1998; 21:987.
5. PA Hollander et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes; a 1-year randomized controlled trial. Diabetes Care 2003; 26:784.